alpha 2 beta adrenoreceptor 301-303 deletion polymorphism in polycystic ovary syndrome

Alexandros D Saltamavros; George Adonakis; Sosanna Kritikou; Vasiliki Koika; Kleanthis Koufogiannis; Kostas Spyropoulos; George Kourounis; Christodoulos Flordellis; Venetsana Kyriazopoulou; Neoklis A Georgopoulos

doi:10.1007/s10286-007-0403-6

alpha 2 beta adrenoreceptor 301-303 deletion polymorphism in polycystic ovary syndrome

Clin Auton Res. 2007 Apr;17(2):112-4. doi: 10.1007/s10286-007-0403-6. Epub 2007 Mar 16.

Authors

Alexandros D Saltamavros¹, George Adonakis, Sosanna Kritikou, Vasiliki Koika, Kleanthis Koufogiannis, Kostas Spyropoulos, George Kourounis, Christodoulos Flordellis, Venetsana Kyriazopoulou, Neoklis A Georgopoulos

Affiliation

¹ Dept of Obstetrics and Gynecology, Division of Reproductive Endocrinology, University of Patras Medical School, University Hospital, Patras, Greece.

PMID: 17370102
DOI: 10.1007/s10286-007-0403-6

Abstract

alpha(2beta) adrenoreceptor 301-303 deletion polymorphism does not influence basal metabolic rate, insulin resistance or weight gain in Greek women with polycystic ovary syndrome.

MeSH terms

Adult
Female
Gene Deletion*
Genotype
Humans
Polycystic Ovary Syndrome / genetics*
Polycystic Ovary Syndrome / pathology
Polymorphism, Genetic / genetics*
Receptors, Adrenergic, alpha-2 / genetics*

Substances

ADRA2B protein, human
Receptors, Adrenergic, alpha-2